Predictive biomarkers for adjuvant capecitabine benefit in early stage triple negative breast cancer in the FinXX clinical trial.

CONCLUSIONS: Genes and metagenes related to anti-tumor immunity, immune response and capecitabine activation could identify TNBC patients who are more likely to benefit from adjuvant capecitabine. Given the reduced power to observe significant findings when correcting for multiplicity, our findings provide the basis for future hypothesis-testing validation studies on larger clinical trials.
PMID: 32005747 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 30, 2020 Category: Cancer & Oncology Authors: Asleh K, Brauer HA, Sullivan A, Lauttia S, Lindman H, Nielsen TO, Joensuu H, Thompson EA, Chumsri S Tags: Clin Cancer Res Source Type: research